Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and a 5-year survival rate of just 12.8%.1 Early diagnosis is rare, leading to advanced disease and chemoresistance, which complicates treatment. Current chemotherapeutic regimens, including gemcitabine (GEM), nab-paclitaxel, 5-fluorouracil, oxaliplatin, irinotecan, and FOLFIRINOX, show modest efficacy.2 Novel therapies are urgently needed to improve outcomes and quality of life for PDAC patients.

Read the full article here

Source: www.gastrojournal.org

Categories: Gastroenterology, General Medicine News

Tags: pancreatic

Tweets with this article

Gastroenterology

Research Letter finds dual targeting of syndecan-1 and glucose transporter-1 with a novel lipid-based delivery system enhances therapeutic efficacy and overcomes chemoresistance in #pancreatic ductal adenocarcinoma ➡️ https://t.co/YYc4qf1UTF https://t.co/d0hsURLCug

Endoscopic sleeve gastroplasty ‘effective alternative’ for MASH, obesity management

Endoscopic sleeve gastroplasty with lifestyle intervention was more effective than lifestyle changes alone in achieving weight loss and histological improvement in patients with metabolic dysfunction-associated…

Healio Gastroenterology January 9, 2025

Hispanic patients with alcohol use disorder face greater odds for hepatitis, cirrhosis

Hispanic patients hospitalized for alcohol use disorder were more likely to develop alcohol-associated hepatitis, decompensated cirrhosis and related complications compared with non-Hispanic white patients, according…

Healio Gastroenterology January 9, 2025

Management and outcomes of antithrombotic therapy in EUS-guided gallbladder drainage

EUS-guided gallbladder drainage (EUS-GBD) is increasingly used for the management of gallbladder disease in patients at high risk for cholecystectomy. These patients often have underlying…

GIE January 9, 2025

ACG Virtual Grand Rounds | ACG

Participate in the ACG Virtual Grand Rounds. This educational series brings together gastroenterology and hepatology experts to share their insights and discuss topics.

ACG January 9, 2025

Gender Inequity in Pharma-Supported Inflammatory Bowel Disease Presentations: Shining a Light on Opportunities for Equality and Transparency in Medical Research

Historically, women have been underrepresented in surgical and procedural disciplines,1 including gastroenterology (GI). Over the past 6 decades, the number of women in these disciplines…

AGA January 9, 2025

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including…

The Lancet Gastroenterology & Hepatology January 9, 2025

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

TACE plus lenvatinib plus pembrolizumab showed significant, clinically meaningful improvement in progression-free survival in patients with unresectable, non-metastatic hepatocellular carcinoma compared with TACE plus placebo.…

The Lancet Gastroenterology & Hepatology January 9, 2025

Related Articles